MedTrace Logo

Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators

NCT01716130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2012-10-29

No results posted yet for this study

Summary

To assess the acceptance of the Fluzone Intradermal (ID)vaccine in adults and vaccine administrators in the United States. Patients completed 2 surveys, one immediately post-vaccination and one seven days later, that documented demographics and assessed their injection pain, injection anxiety, speed of injection, overall satisfaction, and preference for next year's vaccine. Vaccine administrators completed one survey assessing ease of vaccine preparation and administration, time required to administer, and safety/risk of needle stick injury for patient and administrator.

Conditions

  • Patient Response to Fluzone ID Vaccine

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Touro University, California

    lead OTHER

Principal Investigators

  • James E Foy, D.O. · Touro University, California

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716130 on ClinicalTrials.gov